文献速递冠心病外科瓣膜外科

心脏手术后输注非红细胞血液制品不降低生存率

Transfusion of non-red blood cell blood products does not reduce survival following cardiac surgery.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-02-24

该研究基于本中心胸外科医师学会数据库2010至2018年心脏手术患者,排除输注红细胞或循环停止者,经倾向性匹配1:1比较395例需非红细胞血液制品(血小板、新鲜冰冻血浆、冷沉淀)患者与395例未输血患者,发现术后死亡率无显著差异,输血组再手术和延长通气更多,长期生存无显著差异。

要点

  • 心脏手术后仅需非红细胞血液制品者与未输血者术后及长期生存相似。
  • 输血组再手术(5.0% vs 2.0%)和延长通气(9.1% vs 4.8%)高于未输血组。
  • 急诊手术、主动脉内球囊反搏和多瓣膜手术与非红细胞血液制品使用显著相关。

核心结论

  • 心脏手术中仅需非红细胞血液制品而未输注红细胞的患者,术后和长期生存与无需血液制品的患者相似。
  • 这些数据基于有限的患者样本,未来研究将有助于提高结果的普遍性。

研究设计与样本

  • 回顾性分析本中心胸外科医师学会数据库2010至2018年心脏手术患者,排除输注红细胞或循环停止者、心脏移植、心室辅助装置、经导管主动脉瓣及循环停止患者。
  • 共8042例符合分析标准,倾向性匹配(1:1;卡钳值=倾向评分logit标准差0.2倍)后,395例需围术期非红细胞血液制品(血小板、新鲜冰冻血浆、冷沉淀)患者与395例未输血患者匹配。

主要发现

  • 中位随访4.5(3.0-6.4)年;输血组接受血小板327例(82.8%)、新鲜冰冻血浆141例(35.7%)、冷沉淀60例(15.2%)。
  • 术后死亡率输血组6例(1.5%) vs 未输血组4例(1.0%),P=0.52,无显著差异。
  • 再手术输血组20例(5.0%) vs 未输血组8例(2.0%),P<0.02;延长通气输血组36例(9.1%) vs 未输血组19例(4.8%),P<0.02。
  • 急诊手术(OR 2.86 [1.72-4.78];P<0.001)、主动脉内球囊反搏(OR 3.24 [1.64-6.39];P<0.001)和多瓣膜手术(OR 4.34 [2.83-6.67];P<0.001)与血液制品使用显著相关。
  • 血液制品输注(HR 1.15 [0.89-1.48];P=0.3)与死亡风险增加无显著关联;两组长期生存无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些数据基于有限的患者样本,未来研究将有助于提高结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The literature supports the assertion that patients undergoing cardiac surgery who receive perioperative packed red blood cell (pRBC) transfusions have increased associated mortality. The aim of the current study is to assess whether there is an association between non-pRBC blood product transfusions and increased mortality. METHODS: Data from our center's Society of Thoracic Surgeons database included patients who underwent cardiac surgery from 2010 to 2018. Patients with pRBC transfusions or circulatory arrest were excluded. Propensity matching was performed (1:1; caliper = 0.2 times the standard deviation of logit of propensity score). Kaplan-Meier estimates and Cox regression were used. Cardiac transplant, ventricular assist devices, transcatheter aortic valves, and patients who had experienced circulatory arrest were excluded from this analysis. RESULTS: A total of 8042 patients met criteria for analysis. Following propensity matching (1:1), 395 patients requiring perioperative non-pRBC blood products (platelets, fresh-frozen plasma, and cryoprecipitate) were matched with 395 nontransfusion patients, yielding equitable patient cohorts. Median follow-up was 4.5 (3.0-6.4) years. Patients received platelets (327 [82.8%]), fresh-frozen plasma (141 [35.7%]), and cryoprecipitate (60 [15.2%]). There was no significant difference in the postoperative mortality (6 [1.5%] vs 4 [1.0%]; P = .52). Reoperation (20 [5.0%] vs 8 [2.0%]; P < .02) and prolonged ventilation (36 [9.1%] vs 19 [4.8%]; P < .02) were greater in the transfusion group. Emergent operation (odds ratio [OR] 2.86 [1.72-4.78]; P < .001), intra-aortic balloon pump (OR 3.24 [1.64-6.39]; P < .001), and multivalve operation (OR 4.34 [2.83-6.67]; P < .001) were significantly associated with blood product use. Blood product transfusion (hazard ratio; 1.15 [0.89-1.48]; P = .3) was not significantly associated with increased mortality risk. There was no significant long-term survival difference between cohorts. CONCLUSIONS: Patients who undergo cardiac surgery requiring blood products alone, without pRBC transfusion, have similar postoperative and long-term survival compared with patients not requiring blood products. These data are based on a limited patient sample, and future studies will aid in improving the generalizability of these results.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Bianco V, Aranda-Michel E, Serna-Gallegos D, et al. Transfusion of non-red blood cell blood products does not reduce survival following cardiac surgery. J Thorac Cardiovasc Surg. 2022. PMID: 35337681. doi:10.1016/j.jtcvs.2022.02.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。